Contact
searchSearch
HMP Global
Login

News

News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology
News
First-Line FOLFOXIRI Plus Bevacizumab for Patients With Metastatic Colorectal Cancer
09/18/2025
Stephanie Holland
According to results from a real-world study, first-line FOLFOXIRI plus bevacizumab demonstrated improved efficacy compared to doublets plus bevacizumab among patients with initially unresectable, liver-only, right-sided and/or RAS or...
According to results from a real-world study, first-line FOLFOXIRI plus bevacizumab demonstrated improved efficacy compared to doublets plus bevacizumab among patients with initially unresectable, liver-only, right-sided and/or RAS or...
According to results from a...
09/18/2025
Oncology
News
Durvalumab and Tremelimumab Plus Ablative Therapy Disappoints Among Patients With Liver-Predominant Metastatic Colorectal Cancer
08/26/2025
Stephanie Holland
According to results from the phase 2 EORTC 1560 trial, durvalumab and tremelimumab plus liver-directed partial local ablative treatment did not lead to radiological response in untreated metastases among patients with liver-predominant...
According to results from the phase 2 EORTC 1560 trial, durvalumab and tremelimumab plus liver-directed partial local ablative treatment did not lead to radiological response in untreated metastases among patients with liver-predominant...
According to results from the...
08/26/2025
Oncology
News
Bevacizumab Added to Trifluridine and Tipiracil Improved Tumor Response Among Patients With Metastatic Colorectal Cancer
08/05/2025
Stephanie Holland
According to post hoc analysis results from the phase 3 SUNLIGHT trial, trifluridine and tipiracil plus bevacizumab improved tumor response compared to trifluridine and tipiracil alone among previously treated patients with metastatic...
According to post hoc analysis results from the phase 3 SUNLIGHT trial, trifluridine and tipiracil plus bevacizumab improved tumor response compared to trifluridine and tipiracil alone among previously treated patients with metastatic...
According to post hoc analysis...
08/05/2025
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improves Health-Related Quality of Life Among Patients With MSI-H/dMMR Metastatic Colorectal Cancer
08/05/2025
Stephanie Holland
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the...
08/05/2025
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improves Health-Related Quality of Life Among Patients With MSI-H/dMMR Metastatic Colorectal Cancer
08/05/2025
Stephanie Holland
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the...
08/05/2025
Oncology
Conference Coverage
Amivantamab Rechallenge Demonstrates Promise in Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Stephanie Holland
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results...
07/24/2025
Oncology
Conference Coverage
Amivantamab Rechallenge Demonstrates Promise in Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Stephanie Holland
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results...
07/24/2025
Oncology
News
Adding Cetuximab to OPTIMOX for Treatment-Naive Patients With RAS Wild-Type Metastatic Colorectal Cancer
07/23/2025
Stephanie Holland
According to final results from the phase 2 EurdaCT trial, mFOLFOX7 plus cetuximab followed by maintenance fluorouracil/folinic acid and cetuximab did not significantly improve outcomes among treatment-naive patients with RAS wild-type...
According to final results from the phase 2 EurdaCT trial, mFOLFOX7 plus cetuximab followed by maintenance fluorouracil/folinic acid and cetuximab did not significantly improve outcomes among treatment-naive patients with RAS wild-type...
According to final results from...
07/23/2025
Oncology
News
Nivolumab Plus Relatlimab Shows Activity For Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer
07/21/2025
Stephanie Holland
Results from a phase 2 trial highlight the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair-proficient colorectal cancer.
Results from a phase 2 trial highlight the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch repair-proficient colorectal cancer.
Results from a phase 2 trial...
07/21/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use